Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in Obesity

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 5, 2010, Pages 1043-1050

  Chan, Dick C ^a   Watts, Gerald F ^a   Gan, Sengkhee ^a   Wong, Annette T Y ^a   Ooi, Esther M M ^a   Barrett, P Hugh R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cardiovascular disease; Lipoprotein metabolism; Liver fat; Obesity; Weight loss

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B100; FETUIN A; INTERLEUKIN 6; RETINOL BINDING PROTEIN 4; STABLE ISOTOPE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ABDOMEN; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DYSLIPIDEMIA; FAT CONTENT; FEMALE; HEALTH PROGRAM; HUMAN; INTRAABDOMINAL FAT; KINETICS; LIVER; LOW FAT DIET; MALE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SCORING SYSTEM; SUBCUTANEOUS FAT; UNIVARIATE ANALYSIS; WEIGHT REDUCTION;

ADIPOSITY; ADULT; AGED; APOLIPOPROTEIN B-100; BODY MASS INDEX; DIET, FAT-RESTRICTED; ENERGY INTAKE; FATTY LIVER; FEMALE; HUMANS; KINETICS; LIPOPROTEINS, VLDL; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; TREATMENT OUTCOME; TRIGLYCERIDES; WEIGHT LOSS;

EID: 77951456827     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.202275     Document Type: Article

References (30)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346: 1221-1231.
2. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27-38.
3. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235-240. (Pubitemid 46400718)
4. Chan DC, Barrett PH, Watts GF. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. Clin Sci. 2004;107:233-249.
5. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Rev. 2000;21:697-738.
6. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk. 2000; 7:325-331.
7. Goldberg IJ, Ginsberg HN. Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterology. 2006;130:1343-1346.
8. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steato-hepatitis. N Engl J Med. 2000;343:1467-1475.
9. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr. 1985;41:810-817.
10. Chan DC, Watts GF, Ng TW, Hua J, Song S, Barrett PHR. Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes Obes Metab. 2006;8:698-702.
11. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:462-468.
12. Dwyer KP, Barrett PH, Chan D, Foo JI, Watts GF, Croft KD. Oxazo-linone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins. J Lipid Res. 2002;43: 344-349.
13. Chan DC, Watts GF, Nguyen MN, Barrett PHR. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics. Arterioscler Thromb Vasc Biol. 2006;26: 590-596.
14. Retzlaff JA, Tauxe WN, Kiely JM, Stroebel CF. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood. 1969;33:649-666.
15. Feldschuh J, Enson Y. Prediction of the normal blood volume: relation of blood volume to body habitus. Circulation. 1977;56:605-612.
16. Beghin L, Duhal N, Poulain P, Hauw P, Lacroix B, Lecerf JM, Bonte JP, Fruchart JC, Luc G. Measurement of apolipoprotein B concentration in plasma lipoproteins by combining selective precipitation and mass spec-trometry. J Lipid Res. 2000;41:1172-1176.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
18. Chan DT, Dogra GK, Irish AB, Ooi EM, Barrett PHR, Chan DC, Watts GF. Chronic kidney disease delays VLDL apoB-100 particle catabolism: potential role of apo C-III. J Lipid Res. 2009;50:2524-2531.
19. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, Yki-Jarvinen H, Boren J. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755-765.
20. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008;134:424-431.
21. Magkos F, Patterson BW, Mohammed BS, Klein S, Mittendorfer B. Women produce fewer but triglyceride-richer very low-density lipoproteins than men. J Clin Endocrinol Metab. 2007;92:1311-1318.
22. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125-1131.
23. Moller L, Stodkilde-Jorgensen H, Jensen FT, Jorgensen JO. Fasting in healthy subjects is associated with intrahepatic accumulation of lipids as assessed by 1H-magnetic resonance spectroscopy. Clin Sci. 2008;114: 547-552.
24. Magkos F, Patterson BW, Mittendorfer B. Reproducibility of stable isotope-labeled tracer measures of VLDL-triglyceride and VLDL-apolipoprotein B-100 kinetics. J Lipid Res. 2007;48:1204-1211.
25. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apoli-poprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002;35: 898-904.
26. Ota T, Gayet C, Ginsberg HN. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest. 2008;118:316-332.
27. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114:842-845.
28. Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2009;11:188-195.
29. Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PHR. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab. 1999;84:2854-2861.
30. Ng TWK, Watts GF, Barrett PHR, Rye KA, Chan DC. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care. 2007;30:2945-2950.